Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Human Immunodeficiency Virus-Type 1”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT00002441
What this trial is testing

Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection

Who this might be right for
HIV InfectionsHIV Seronegativity
VaxGen 5,000
Testing effectiveness (Phase 2)Study completedNCT02099994
What this trial is testing

Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan Adults

Who this might be right for
AIDS
University of Oxford 72
Post-approval studies (Phase 4)Ended earlyNCT00981773
What this trial is testing

The St. Marys and The Mater Switch Study

Who this might be right for
HIV Infections
Imperial College London 18
Not applicableStudy completedNCT03500172
What this trial is testing

HIV Treatment Retention Interventions for Women Living With HIV (Siyaphambili Study)

Who this might be right for
HIV-1 Virologic Response
Johns Hopkins Bloomberg School of Public Health 1,391
Testing effectiveness (Phase 2)Study completedNCT00056641
What this trial is testing

Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

Who this might be right for
HIV Infections
Boehringer Ingelheim 328
Testing effectiveness (Phase 2)Ended earlyNCT00865566
What this trial is testing

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 2,504
Very early researchLooking for participantsNCT06252402
What this trial is testing

CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS

Who this might be right for
HIV-1
City of Hope Medical Center 15
Early research (Phase 1)Study completedNCT00002353
What this trial is testing

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects

Who this might be right for
HIV Infections
United Biomedical
Large-scale testing (Phase 3)Study completedNCT00421551
What this trial is testing

Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136

Who this might be right for
HIV Infections
French National Agency for Research on AIDS and Viral Hepatitis 225
Post-approval studies (Phase 4)UnknownNCT00011895
What this trial is testing

Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Who this might be right for
HIV Infections
GlaxoSmithKline 400
Large-scale testing (Phase 3)Study completedNCT02121795
What this trial is testing

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

Who this might be right for
HIV-1 Infection
Gilead Sciences 668
Not applicableStudy completedNCT00618371
What this trial is testing

Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia

Who this might be right for
HIV Infection
University of Pittsburgh 10
Not applicableEnrolling By InvitationNCT02699736
What this trial is testing

EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV

Who this might be right for
HIVHepatitis BHepatitis C+10 more
Rigshospitalet, Denmark 23,000
Testing effectiveness (Phase 2)Study completedNCT02716675
What this trial is testing

Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 2,699
Very early researchStudy completedNCT04791007
What this trial is testing

OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults

Who this might be right for
HIV Prevention
Orion Biotechnology Polska Sp. z o.o. 60
Large-scale testing (Phase 3)UnknownNCT04022967
What this trial is testing

ANRS 12372 MODERATO Study

Who this might be right for
HIV-1-infection
ANRS, Emerging Infectious Diseases 480
Not applicableLooking for participantsNCT07186244
What this trial is testing

Prevention ICONA Dedicated Ensemble

Who this might be right for
PrEPPrEP Adherence MonitoringHIV+3 more
Fondazione ICONA 5,000
Testing effectiveness (Phase 2)Study completedNCT02578706
What this trial is testing

Targeting Platelets in Chronic HIV Infection

Who this might be right for
HIV-1 Infection
Icahn School of Medicine at Mount Sinai 27
Early research (Phase 1)Study completedNCT04006704
What this trial is testing

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

Who this might be right for
HIV-1
Janssen Pharmaceutica N.V., Belgium 25
Early research (Phase 1)Looking for participantsNCT07481175
What this trial is testing

Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)

Who this might be right for
HIV-1
Thomas Aagaard Rasmussen 38
Next Page